Summit Therapeutics Inc. (SMMT)

NASDAQ: SMMT · IEX Real-Time Price · USD
1.00
+0.11 (12.22%)
At close: Aug 8, 2022 4:00 PM
1.01
+0.01 (1.00%)
After-hours: Aug 8, 2022 7:35 PM EDT
12.22%
Market Cap 98.12M
Revenue (ttm) 1.87M
Net Income (ttm) -92.51M
Shares Out 98.12M
EPS (ttm) -0.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 80,338
Open 0.96
Previous Close 0.89
Day's Range 0.95 - 1.01
52-Week Range 0.88 - 8.39
Beta 1.04
Analysts Sell
Price Target 4.08 (+308.0%)
Earnings Date Aug 9, 2022

About SMMT

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infecti... [Read more...]

Industry Biotechnology
Founded 2003
Employees 105
Stock Exchange NASDAQ
Ticker Symbol SMMT
Full Company Profile

Financial Performance

In 2021, SMMT's revenue was 1.81 million, an increase of 110.35% compared to the previous year's 860,000. Losses were -88.60 million, 68.1% more than in 2020.

Financial numbers in GBP Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for SMMT stock is "Sell." The 12-month stock price forecast is 4.08, which is an increase of 308.00% from the latest price.

Price Target
$4.08
(308.00% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Summit Therapeutics' Rights Offering Nearing Expiration Date

Summit Provides Preliminary Update on Financial Position Summit Provides Preliminary Update on Financial Position

Summit Therapeutics Appoints Dr. Maky Zanganeh as Co-CEO & President

Bob Duggan Remains Chairman of the Board of Directors and CEO Bob Duggan Remains Chairman of the Board of Directors and CEO

Summit Therapeutics Announces Commencement of $100 Million Rights Offering

Menlo Park, CA, July 18, 2022 (GLOBE NEWSWIRE) --  Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it has commenced its previously-announced rights offering of up to $100 million of the Com...

Summit Therapeutics Provides Update on Ridinilazole

Menlo Park, CA, July 14, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today provided an update with respect to the clinical development of ridinila...

Summit Therapeutics Announces $100 Million Rights Offering

Menlo Park, CA, June 22, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that the Company's Board of Directors has approved a rights offering...

Summit Therapeutics' Upcoming Annual Shareholders' Meeting

Rescheduled to June 16, 2022, at 1:00pm Eastern Time Rescheduled to June 16, 2022, at 1:00pm Eastern Time

Summit Therapeutics Appoints Ankur Dhingra as Chief Financial Officer

Cambridge, MA, June 01, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Ankur Dhingra has been appointed as Chief Financial Officer, effective immediately.

Summit Therapeutics Inc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2022

Cambridge, MA, May 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progr...

Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended Dece...

Summit Therapeutics perceives multiple opportunities to expand across the microbiome therapeutics field Summit Therapeutics perceives multiple opportunities to expand across the microbiome therapeutics ...

Summit Therapeutics Announces Rights Offering

Cambridge, Massachusetts, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that the Company's Board of Directors has approved a right...

Summit Therapeutics Today Presents Its Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference

Cambridge, Massachusetts, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) reminds interested stakeholders that it will today present the Company's v...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Summit Therapeutics Inc. - SMMT

NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advised to ...

Summit Therapeutics to Present Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference

Cambridge, Massachusetts, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that it will present the Company's vision and its intended...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Summit Therapeutics Inc. with Losses of $100...

LOS ANGELES, Dec. 31, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Summit Therapeutics Inc...

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Summit Therapeutics Inc. with Losses of $100,000 to ...

LOS ANGELES--(BUSINESS WIRE)---- $SMMT #SMMT--INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Summit Therapeutics Inc. with Losses of $100,000 to Contact the Firm

Summit Therapeutics' Infection Candidate Flunks In Head-To-Head Trial

Summit Therapeutics Inc (NASDAQ: SMMT) shares are trading lower after disappointing results from the Phase 3 Ri-CoDIFy study of ridinilazole for C. difficile infection (CDI).

Why Summit Therapeutics Stock Is Tumbling Today

The company just revealed disappointing phase 3 trial results for its only clinical-stage drug candidate.

Summit Therapeutics Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection

Cambridge, MA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced topline results for the Phase III Ri-CoDIFy study evaluating its inve...

Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ende...

Cambridge, Massachusetts, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its o...

Summit Therapeutics Bolsters Its Board of Directors with Seasoned Regulatory & Clinical Research Executive Dr. Urte G...

Cambridge, Massachusetts, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Dr. Urte Gayko, PhD, has been appointed to our Board of Directors, effective imme...

Summit Therapeutics Appoints Prominent Biotech Attorney and Advisor Kenneth A. Clark to Its Board of Directors

Cambridge, MA, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Kenneth A. Clark, JD, has been appointed to our Board of Directors, effective immediately. M...

(SMMT) Alert: Did You Lose Money on Your Summit Therapeutics Investment? Contact Johnson Fistel Regarding Investigation

SAN DIEGO, Oct. 2, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by Summit Therapeutics Inc. ("Summit" or the ...

Summit Therapeutics Presents Further Breakthrough Insights Surrounding the Novel Mechanism of Action for its Investig...

Cambridge, Massachusetts, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying an important ePoster at IDWeek 2021. IDWeek is the jo...

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021

WASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today a...

FDA Not In Favor Of Summit Therapeutics' Endpoint Change To Pivotal Infection Trials

Summit Therapeutics Inc (NASDAQ: SMMT) announced that the FDA disagrees with its proposed change to the primary endpoint in Phase 3 Ri-CoDIFy studies. In a regulatory filing, the Company said that the f...